Analysis of therapeutic effectiveness in 158 childhood acute lymphoblastic leukemia patients treated with ALL-XH-99 protocol / 中华血液学杂志
Chinese Journal of Hematology
;
(12): 1-4, 2004.
Article
in Chinese
| WPRIM
| ID: wpr-291464
ABSTRACT
<p><b>OBJECTIVE</b>To analyse the treatment outcome of 158 childhood acute lymphoblastic leukemia (ALL) patients, and explore how to improve the event-free survival (EFS) rate in ALL.</p><p><b>METHOD</b>All of the patients entered the ALL-XH-99 clinical trial. Kaplan-Meier method was used to estimate survival rates and differences were compared with the 2-sided log-rank test, statistics was done by SPSS.</p><p><b>RESULTS</b>Out of the 158 patients, 153 (96.8%) attained complete remission (CR) in a median time of 33 days. The overall EFS rate at 5 years was (72.4 +/- 7.8)% with a median observation duration of 26 months. The EFS rates at 5 years in low-risk (LR), median-risk (MR) and high-risk (HR) groups were (88.9 +/- 5.5)%, (78.5 +/- 8.0)% and (53.4 +/- 10.9)%, respectively (P < 0.05). Relapse occurred in 15 patients (10.0%) in a median time of 12 months, including 13 isolated hematologic relapses, 2 isolated central nervous system (CNS) relapses. Seven patients died of complications, and 13 died of leukemia relapse.</p><p><b>CONCLUSION</b>The early response to therapy was an important independent prognostic factor, high-dose methotrexate (HD-MTX) was effective for preventing haematological and testicular relapse. The ALL-XH-99 protocol decreased the rate of therapy-related death and improved the long-term event-free survival rate.</p>
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Antineoplastic Combined Chemotherapy Protocols
/
Survival Rate
/
Mortality
/
Therapeutic Uses
/
Drug Therapy
/
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Type of study:
Practice guideline
/
Prognostic study
Limits:
Adolescent
/
Child
/
Child, preschool
/
Female
/
Humans
/
Infant
/
Male
Language:
Chinese
Journal:
Chinese Journal of Hematology
Year:
2004
Type:
Article
Similar
MEDLINE
...
LILACS
LIS